Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.56 |
| ▸ | INSR | P06213 | 6/20 | 0.56 |
| ▸ | IGF1R | P08069 | 6/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217781 | 0.86 | ALK (0.62) | ALKINSRIGF1RCCNA2CDK2 | |
| SCHEMBL16656851 | 0.84 | INSR (0.60) | ALKINSRIGF1RAURKA | |
| SCHEMBL11916403 | 0.84 | JAK2 (0.63) | ALKINSRIGF1RCCNA2CDK2 | |
| SCHEMBL15217784 | 0.83 | ALK (0.82) | ALKINSRIGF1RAURKA | |
| SCHEMBL21446901 | 0.82 | CCNA2 (0.48) | ALKINSRCCNA2CDK2PTK2 | |
| SCHEMBL19203805 | 0.81 | ALK (0.53) | ALKINSRIGF1RCCNA2CDK2 | |
| SCHEMBL11916315 | 0.81 | ALK (0.53) | ALKINSRIGF1RCCNA2CDK2 | |
| SCHEMBL11901091 | 0.80 | ALK (0.73) | ALKINSRIGF1RPTK2 | |
| SCHEMBL19203872 | 0.77 | LRRK2 (0.69) | ALKINSRIGF1RPTK2MAPK9 | |
| SCHEMBL15424352 | 0.75 | ALK (0.41) | ALKIGF1RCCNA2CDK2MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885IGF1R 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.